Related references
Note: Only part of the references are listed.Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme
Jackie D. Corbin et al.
CELLULAR SIGNALLING (2009)
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct
Jayvardhan Pandit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The properties of phosphodiesterase 11A4 GAF domains are regulated by modifications in its N-terminal domain
Marco Gross-Langenhoff et al.
FEBS JOURNAL (2008)
Solution structure of the cGMP binding GAF domain from phosphodiesterase 5 - Insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change
Clemens C. Heikaus et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change
Sergio E. Martinez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP
Noriko Handa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains
Karina Hofbauer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Direct Allosteric Regulation between the GAF Domain and Catalytic Domain of Photoreceptor Phosphodiesterase PDE6
Xiu-Jun Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Overview of PDEs and their regulation
Kenji Omori et al.
CIRCULATION RESEARCH (2007)
Phosphodiesterases in the CNS: targets for drug development
Frank S. Menniti et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
C Lugnier
PHARMACOLOGY & THERAPEUTICS (2006)
cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11
M Gross-Langenhoff et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Improving memory: A role for phosphodiesterases
A. Blokland et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
Andrew T. Bender et al.
PHARMACOLOGICAL REVIEWS (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphodiesterase-4 as a therapeutic target
MD Houslay et al.
DRUG DISCOVERY TODAY (2005)
Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation
R Zoraghi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: Modes of ligand binding and dimerization
SE Martinez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
BJ Lipworth
LANCET (2005)
Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins
R Zoraghi et al.
MOLECULAR PHARMACOLOGY (2004)
Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A
AY Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
PDE5 is converted to an activated state upon cGMP binding to the GAF A domain
SD Rybalkin et al.
EMBO JOURNAL (2003)
Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity
SH Francis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
PHENIX:: building new software for automated crystallographic structure determination
PD Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2002)
Binding of cGMP to GAF domains in amphibian rod photoreceptor cGMP phosphodiesterase (PDE)
M Yamazaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding
SE Martinez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Phosphodiesterase 5 inhibitors: Current status and potential applications
DP Rotella
NATURE REVIEWS DRUG DISCOVERY (2002)
Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase
L Liu et al.
CELLULAR SIGNALLING (2002)
Share Paper
